XCUR Stock Forecast: Exicure, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.91
−6.89% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$6.4M
Ticker Nerd rank
61/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$1.1M
Net income−$1.1M
Free cash flow−$887K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.5%
1M
−8.7%
YTD
−83.2%
1Y
−78.2%
From 52W high
−87.5%
From 52W low
+2.5%
$0.89
$7.29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Exicure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
61/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
83
Growth
73
Issuance
60
Quality
60
Volatility
52
Value
52
Momentum
24
Revisions
20

Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (20): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XCUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XCUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26XCUR

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Of the 10 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
16 Aug 2022Chardan CapitalMaintainsNeutral$0.25 → $2.00
13 Dec 2021Chardan CapitalDowngradeNeutral$2.25 → $0.40
23 Nov 2021Chardan CapitalMaintainsBuy$7.00 → $2.25
17 May 2021HC Wainwright & Co.MaintainsBuy$8.00 → $6.00
18 Dec 2020BMO CapitalInitiatesOutperform—
17 Sept 2020Chardan CapitalMaintainsBuy$5.00 → $7.00
20 Nov 2019GuggenheimInitiatesBuy—
6 Nov 2019H.C. WainwrightInitiatesBuy—
26 Mar 2019Chardan CapitalInitiatesBuy—
11 July 2018Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XCUR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XCUR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Exicure, Inc. returned −78.2% against +6.9% for the S&P 500, dividends included.

XCUR vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26XCURS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XCUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
6.7×

Cheaper than 12% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−168.4%

Higher than 8% of US stocks

Return on assets
−30.3%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Exicure, Inc. has a market value of $6.4M and an enterprise value of $4.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$8.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.4M.

  • Shares outstanding: 6.4M.

  • Exicure, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

XCUR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XCURExicure, Inc.$6.4M61
TPSTTempest Therapeutics, Inc.$5.7M53
EVGNEvogene Ltd.$5.7M38
LGVNLongeveron, Inc.$5.6M44
OPHICollPlant Biotechnologies Ltd.$5.9M28
TOVXTheriva Biologics, Inc.$5.5M30
ENVBEnveric Biosciences, Inc.$6.0M16

Take a look at XCUR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Exicure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about XCUR

How does Ticker Nerd's model rank XCUR?

As at 21 Nov 2026, Exicure, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).

What is the XCUR stock forecast for 2030?

No analyst covering Exicure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XCUR are extrapolating price history, which says nothing about the business.

How has XCUR stock performed over the past year?

Exicure, Inc. returned -78.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Exicure, Inc. do?

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for blood-related diseases and other serious medical conditions. Its current focus includes small-molecule medicines designed to influence cellular signaling and mobilization, particularly through inhibition of the CXCR4 chemokine receptor.

Company

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for blood-related diseases and other serious medical conditions. Its current focus includes small-molecule medicines designed to influence cellular signaling and mobilization, particularly through inhibition of the CXCR4 chemokine receptor. The company’s lead clinical-stage asset, GPC-100, also known as burixafor, is being evaluated for its ability to mobilize hematopoietic stem cells and lymphocytes, supporting potential applications in hematology and oncology. Exicure, Inc. also maintains expertise in nucleic-acid-based drug development, including therapeutic platforms centered on spherical nucleic acids for immuno-oncology and genetic disorders. As a clinical-stage biotechnology business, the company’s role in the financial market is linked to the development and advancement of specialized pharmaceutical candidates rather than the commercial sale of a broad portfolio of approved medicines. Its activities place it within the biotechnology and pharmaceutical sectors, serving research, clinical-development, and healthcare markets.

CEO Mr. Jungsoo Kim · 1 employees · United States · https://www.exicuretx.com